Escalating Pipeline of ADCs Would Lead to Future Trends in Market Various biopharmaceutical companies are developing ADCs owing to the rising interest in ADCs as promising cancer treatment. According to an article, “Antibody-Drug Conjugates Clinical Trial Pipeline Experiences Momentum,” published in June 2023, over 300 ADCs are under development with the involvement of more than […]